Biogen’s new Alzheimer’s drug to raise Medicare costs (NASDAQ:BIIB)

Leqembi, the new Alzheimer’s therapy developed by Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY), could add $2B – $5B costs to Medicare annually, in the event of broader coverage, according to a recently published study.

Early this year, the FDA granted FDA’s accelerated approval for the anti-amyloid antibody, which comes with a $26.5K annual list price and additional costs for administration.